Exenatide Once Monthly Showed Positive Results in Phase 2 Study

March 14, 2011

Press release from Eli Lilly

Amylin Pharmaceuticals, Eli Lilly and Company Alkermes, Inc., announce positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

The 121-patient, phase 2 study assessed the efficacy, safety and tolerability of three different doses of exenatide once monthly.

Article information
Pharmaceutical industry
Eli Lilly
March 14, 2011
Free HCP newsletter
Join the newsletter
Free weekly news
Latest diabetes healthcare news direct to your inbox.
NHS employee:
Latest forum posts
The latest forum threads from the Ask a Question forum.
Healthcare Search